|
gptkbp:instanceOf
|
gptkb:drug
gptkb:bisphosphonate
|
|
gptkbp:approvedBy
|
1995
|
|
gptkbp:ATCCode
|
M05BA04
|
|
gptkbp:bioavailability
|
0.6%
|
|
gptkbp:brand
|
gptkb:Fosamax
|
|
gptkbp:CASNumber
|
121268-17-5
|
|
gptkbp:chemicalFormula
|
C4H13NO7P2
|
|
gptkbp:contraindication
|
hypocalcemia
esophageal abnormalities
|
|
gptkbp:discoveredBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:eliminationHalfLife
|
over 10 years (in bone)
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits osteoclast-mediated bone resorption
|
|
gptkbp:metabolism
|
not metabolized
|
|
gptkbp:molecularWeight
|
249.1 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gastrointestinal upset
musculoskeletal pain
esophageal irritation
|
|
gptkbp:synonym
|
gptkb:alendronate
4-amino-1-hydroxybutylidene bisphosphonate
|
|
gptkbp:usedFor
|
gptkb:bone
gptkb:Paget's_disease_of_bone
|
|
gptkbp:bfsParent
|
gptkb:M70AB1
gptkb:M70AB2
gptkb:M70AB3
gptkb:M01AH01
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
alendronic acid
|